Wistar's Dr. Abdel-Mohsen has identified sugar abnormalities in the blood that may promote biological aging and inflammation in people living with HIV.
The Wistar Institute Appoints Max Berger to its Board of Trustees
Wistar Institute’s Dr. Mohamed Abdel-Mohsen has demonstrated a connection between viral damage to the gut and premature biological aging.
Wistar Institute is pleased to announce the recruitment of Irene Bertolini, Ph.D., to pursue research in breast and brain cancers.
Jessie Villanueva, Ph.D., is one of the recipients of the 2024 Diversity in Business Award from the Philadelphia Business Journal.
The Wistar Institute is pleased to announce the recruitment of Filippo Veglia, Ph.D., to the Ellen and Ronald Caplan Cancer Center, where he joins Wistar’s Immunology, Microenvironment and Metastasis Program as an Assistant Professor.
The Wistar Institute is pleased to welcome Aleister Saunders, Ph.D., and Patrick Oates, Ph.D., to its Board of Trustees. The two new trustees bring a wealth of experience in biomedical research, technology transfer, and drug development to Wistar’s mission.
Wistar researchers successfully tested a simple intervention that could unlock greater anti-tumor power in therapies that use T cells — an approach known as “cell-based therapy,” which uses specially designed T cells to fight cancer.
Dario C. Altieri, M.D. — The Wistar Institute’s president and CEO, director of its Ellen and Ronald Caplan Cancer Center and the Robert & Penny Fox Distinguished Professor — is a recipient of the 2023 Most Admired CEO Awards recognized by the Philadelphia Business Journal for his leadership and service to Wistar.
The Wistar Institute announces the appointment of Dean Stoios as Chief Financial Officer.
Dario C. Altieri, M.D., Wistar president and CEO, will be honored by the Justinian Foundation and Society of Philadelphia for exemplifying the finest qualities of scholarship, civic leadership and integrity.
Zachary Schug, Ph.D., assistant professor at The Wistar Institute, has published a new paper in the journal Nature Cancer demonstrating a double-acting mechanism for fighting a particularly aggressive, difficult-to-treat form of breast cancer.
Wistar is pleased to announce the recruitment of Avi Srivastava, Ph.D., to the Ellen and Ronald Caplan Cancer Center, where he joins Wistar’s Gene Expression and Regulation Program as an Assistant Professor.
Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio.
The Wistar Institute is pleased to announce the appointment of Alexander Price, Ph.D., as assistant professor in the Gene Expression and Regulation Program of the Ellen and Ronald Caplan Cancer Center at The Wistar Institute.
The Wistar Institute, a global leader in biomedical research in cancer, immunology and infectious disease, is pleased to welcome Joy Taylor to its Board of Trustees. Taylor is CEO of EastEdge Consulting Services, a Pennsylvania-based management consulting firm focused on organizational and operational improvement.
Scientists have long used community advisory boards to engage communities and provide feedback on studies, but this model has limitations. Now, Wistar Institute researchers are sharing how a more inclusive model for community engagement can lead to deeper insights and greater community participation in HIV research.
Wistar hosts its 27th Jonathan Lax Memorial Lecture Thursday, June 29th at 5:30 pm EST.
PHILADELPHIA — (June 20, 2023) — When cancer that starts in the body metastasizes to the brain, it is almost always lethal, in part because so few treatment options exist. Now a new study by Wistar scientists published in Nature Communications shows that a type of brain cell called astrocytes plays an important role in promoting brain metastasis by recruiting a specific subpopulation of immune cells.
Wistar is pleased to welcome Sozi Tulante to its Board of Trustees. He is currently General Counsel of Form Energy, a Massachusetts-based energy storage technology and manufacturing company.
Wistar Institute has formed a collaboration with the Pennsylvania Biotechnology Center and the Baruch S. Blumberg Institute to accelerate the advancement of “bench to bedside” biomedical research discoveries in the tri-state region.
Wistar Institute researchers have uncovered a key mechanism as to how p53 suppresses tumors.
Wistar Institute researchers identified hopeaphenol, a natural plant-based compound, as possessing antiviral properties that are effective against HIV.
Wistar scientists have identified a gene signature that accurately predicts the functioning of P53 variants, important information to assessing cancer risk and optimizing choices for cancer therapeutics.
The Cotswold Foundation Postdoctoral Fellowship is a new fellowship totaling $500,000 over the course of five years to support a postdoctoral researcher studying immunology, cancer research, or vaccine biology at The Wistar Institute.
The Wistar Institute, which has recently launched a $75 million programmatic campaign investing in biomedical advances, announces the appointment of Michael Criscuolo as Vice President of Development.
amfAR, The Foundation for AIDS Research, has awarded Luis J. Montaner, D.V.M., D.Phil., in collaboration with Mohamed Abdel-Mohsen, Ph.D., a Target Grant for $397,663 over two years.
Maureen Murphy, Ph.D., has been named Deputy Director of the Ellen and Ronald Caplan Cancer Center at The Wistar Institute. Murphy will guide the growth of the Cancer Center through expanding research initiatives and collaboration, education and training programs, and recruitment to fast-track innovative basic cancer research discoveries into future transformative drugs and therapies.
The Wistar Institute Biomedical Technician Training (BTT) Program was awarded Workforce Champion of the Year in the 3rd Annual 2022 BioBuzz Awards. The program is a collaborative that includes The Wistar Institute, West Philadelphia Skills Initiative, Iovance Biotherapeutics, PIDC, and others.
The Wistar Insitute, William Way Community Center, Philadelphia FIGHT, BEAT-HIV Delaney Collaboratory, Philadelphia Foundation, and The Penn Center for AIDS Research are proud to announce that “The London Patient” Adam Castillejo will take part in a panel conversation and Q&A on Wednesday, October 26 from 5 to 8 pm
In a research paper published in PLOS ONE, The Wistar Institute's Dario C. Altieri, M.D., alongside national and international collaborators, distinguish a specific gene signature indicative of mitochondrial reprogramming in tumors that correlates with poor patient outcome.
The National Institutes of Health has awarded Amelia Escolano, Ph.D., assistant professor in The Wistar Institute’s Vaccine & Immunotherapy Center, the 2022 NIH Director’s New Innovator Award.
Currently, the only FDA approved biomarker for ICI melanoma treatment is the tumor mutation burden assay, but the mechanisms linking it to ICI remain unclear. However, new research out of The Wistar Institute now provides evidence of novel, reliable biomarkers that predict therapy response using advanced computer technology.
The Wistar Institute is pleased to announce the appointment of Michele A. Schiavoni, M.S., as Vice President of Communications & Marketing, in a central leadership role that will bolster the visibility of the Institute’s ambitious biomedical research science initiatives and programs advancing the organization’s newly launched Bold Science // Global Impact Capital Campaign.
Researchers in the laboratory of Yulia Nefedova, M.D., Ph.D., at The Wistar Institute and collaborators at Jubilant Therapeutics Inc. have uncovered a novel mechanism by which protein arginine deiminase 4 (PAD4) in neutrophils promotes cancer progression. The paper also found that inhibition of this function of PAD4 reduces primary tumor growth and metastasis and enhances checkpoint inhibitor treatments.
The National Cancer Institute (NCI) has granted a Merit Extension Award to The Wistar Institute’s Ellen and Ronald Caplan Cancer Center totaling more than $5 million.
Published today in Nature Cell Biology, Wistar scientists revealed a novel ADAR1-SIRT1-p16INK4a axis in regulating cellular senescence and its potential implications in tissue aging.
The Wistar Institute announces the appointment of Gelvina Rodriguez Stevenson, Esq., as vice president, general counsel, secretary and government relations.
Under a Defense Advanced Research Projects Agency (DARPA) and Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) funded program, a novel COVID-19 antibody delivery approach has advanced to clinical trials.
Wistar announces that for the first time it will globally stream its 26th Annual Jonathan Lax Memorial Award Lecture, celebrating 26 years of providing state-of-research updates to the community, on Tuesday, June 28 from 9:30 to 11:00 a.m. EST.
Wistar scientists identified that inhibiting therapeutic target KDM5A boosts a person’s immune response to tumors.
Wistar Institute announces its Bold Science // Global Impact Capital Campaign to support a five-year plan that sets out Wistar’s roadmap for accelerated progress to drive breakthroughs in biomedical science and technology and educate and train the next generation of innovators.
Wistar Institute scientists take a promising step in the direction of developing an HIV vaccine that uses a unique native-like trimer to develop Tier-2 neutralizing antibodies—the kind that matter for combatting HIV—in mice for the first time.
The first generation of COVID-19 vaccines have been highly effective, but also have limitations. Now Wistar scientists have developed a more targeted vaccine that, in animal studies, shows stronger, broader, and more durable protection in a single, low dose.
A new study by Wistar researchers has identified a new potential pathway for developing therapeutics that target Epstein-Barr virus (EBV).
Wistar announces the initiation of a Phase 2 clinical study of VK-2019 in patients with advanced Epstein-Barr Virus (EBV)-positive nasopharyngeal carcinoma (NPC) and lymphoma.
Fox Chase Cancer Center has opened an investigator-initiated, phase 1 clinical trial to evaluate the safety and efficacy of gamitrinib in patients with advanced cancer.
Scientists at The Wistar Institute have identified two genes that play a critical role in protecting ovarian cancer from the immune system.
The Commonwealth of Pennsylvania has granted The Wistar Institute $4 million to fund COVID-19 research focused on understanding the impact of COVID-19 on certain at-risk populations and supporting the commonwealth’s preparation and emergency response planning for future pandemics.
A new Wistar Institute study shows how key features on the surface of HIV-infected cells help the disease evade detection by the immune system.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right